Trianon Scientific Communication

20/09/2026

28/08/2026

Which sustainability moves actually expand your margin - not just your report? I ask because we’ve tested them across pharma, agro-food and textiles and the results are clear. 1) Process yield optimization: cut waste streams with targeted catalyst and heat-recovery upgrades - typical EBITDA uplift 3-7% for mid-size plants. 2) Raw-material sourcing shift: substitute 10-20% high-impact inputs with circular or bio-based alternatives - lowers COGS by 2-5% while reducing compliance risk. 3) Energy intensity reduction via electrification and smart controls: 15-30% lower energy spend in many facilities, shrinking operating costs and emissions simultaneously. You’re juggling tight regulations, limited CAPEX and complex supply chains. We help you prioritize the levers that pay back fastest and scale across sites. Ready to see which two moves will move your bottom line this quarter? Learn more: https://wix.to/0AGGWa4

26/08/2026

Are your sustainability targets fuzzy-and quietly draining profits? We see it all the time: vague goals, siloed teams, and initiatives with no numbers attached. That’s waste. That’s margin erosion. We diagnose the root systemic barrier, apply Trianon’s P³ method, and turn guesswork into a measurable profit lift. Want a real example and a clear path forward? Visit https://wix.to/gzgeySu and let’s fix this together.

29/06/2026

𝐘𝐨𝐮𝐫 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐢𝐬 𝐌𝐚𝐧𝐮𝐚𝐥 𝐃𝐨𝐞𝐬𝐧'𝐭 𝐈𝐧𝐜𝐥𝐮𝐝𝐞 𝐌𝐲 𝐒𝐤𝐢𝐧 - 𝐖𝐡𝐞𝐧 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐓𝐫𝐚𝐢𝐧𝐢𝐧𝐠 𝐌𝐢𝐬𝐭𝐚𝐤𝐞𝐬 𝐃𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐟𝐨𝐫 𝐃𝐞𝐯𝐢𝐚𝐭𝐢𝐨𝐧

𝐌𝐞𝐞𝐭 𝐭𝐡𝐞 𝐬𝐩𝐞𝐚𝐤𝐞𝐫!

Dr. Nathalie Sène graduated from ULB in 2016. Since then she has built a practice most dermatologists do not have: skin allergy testing, darker phototypes, aesthetic medicine, all under one roof, all informed by the patients medical training tends to leave out of the textbook.

She sits on the Royal Belgian Society for Dermatology and Venerology, the Société Belge de Médecine Esthétique, and the Société Française des Lasers en Dermatologie.
She works at Brussels Skin Center in the European Quarter, a clinic that puts her in front of patients from every background the EU institutions bring to this city. That is not incidental to her expertise. It is the reason she has it.

On 30 June, she joins our roundtable at The Nine to talk about what happens when a diagnostic standard built on 12% of the population gets applied to the other 88%.

Details and registration:

📅 June 30th
🕣 7.30pm
🏩 The Nine
🎟️https://www.science-by-trianon.com/event-details/your-diagnosis-manual-doesnt-include-my-skin

26/06/2026

A super El Niño is forming in the Pacific. NOAA puts the odds above 60 percent it rivals 1997, the year that triggered billions in losses across agriculture, insurance, and shipping.

Here is the part your CSRD transition plan probably does not cover.
Most climate transition plans model gradual, linear change.

Average temperature rise, average sea level, average rainfall shift, all extrapolated in a straight line out to 2030 or 2050. El Niño does not move in a straight line. It is a six to twelve month spike layered on top of the existing 1.4 to 1.5 degrees of warming we already carry. It hits specific regions hard, fast, and asymmetrically. Drought flips to flood. Flood flips to drought. Fisheries collapse in one basin while another floods with stock.

A transition plan built entirely on long-term averages will say nothing useful about what happens to your supply chain this winter.

This matters for three reasons specific to CSRD and TCFD-aligned reporting.

One. Physical risk disclosure under ESRS E1 asks you to identify acute and chronic risks separately. El Niño is the textbook acute event. If your materiality assessment only lists chronic, gradual risks, an auditor is going to ask why you excluded the acute category that is forming in real time.

Two. Scenario analysis loses credibility fast if it cannot explain a known, named, currently forecast event. "We did not model El Niño" is not a defensible answer in front of a board or an assurance provider eighteen months from now.

Three. Supplier concentration risk. If your scope 3 mapping has not been cross-referenced against documented El Niño-sensitive geographies, you have a gap that is visible to anyone who knows where to look. Peru, Indonesia, Australia, the US Southwest, parts of East Africa.

The fix is not a new framework. It is one additional column in the risk register you already have: which of our top suppliers and facilities sit inside a known ENSO-sensitive zone, and what is the documented exposure if this event peaks as a strong or very strong El Niño this winter.

That column either exists in your file by the next board cycle, or it gets discovered by your auditor first.

Experts say climate pattern could supercharge extreme weather events and push temperatures to record highs

24/06/2026

[EVENT] 𝐘𝐨𝐮𝐫 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐢𝐬 𝐌𝐚𝐧𝐮𝐚𝐥 𝐃𝐨𝐞𝐬𝐧'𝐭 𝐈𝐧𝐜𝐥𝐮𝐝𝐞 𝐌𝐲 𝐒𝐤𝐢𝐧 - 𝐖𝐡𝐞𝐧 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐓𝐫𝐚𝐢𝐧𝐢𝐧𝐠 𝐌𝐢𝐬𝐭𝐚𝐤𝐞𝐬 𝐃𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐟𝐨𝐫 𝐃𝐞𝐯𝐢𝐚𝐭𝐢𝐨𝐧

Medical textbooks show melanoma on white skin.

Rashes on white skin.

Inflammatory disease on white skin.
That training set represents 12% of the global population.
The result: a melanoma on Black skin does not match the photo in the manual. So it gets missed. Or caught late. Late is the difference between treatable and terminal.
On 30 June we are hosting a roundtable at The Nine, Brussels. Two dermatology specialists break down what standard training left out: how skin conditions present across different melanin levels, why diagnostic criteria delay care for Black patients, and what it takes to retrain a clinical baseline that was wrong from the start.
Bring your questions. Bring the diagnosis that never quite added up.

Details and registration:

📅 June 30th
🕣 7.30pm
🏩 The Nine
🎟️https://www.science-by-trianon.com/event-details/your-diagnosis-manual-doesnt-include-my-skin

22/06/2026

Brussels deregulated gene-edited crops to save the planet. Convenient that it also saves Bayer.
On 17 June, the EU approved new rules on gene-edited crops. Under 20 genetic modifications, treated like a conventional crop. No risk assessment. No traceability. No label on the food.
The reasons given are real. Climate adaptation. Food security. Competitiveness against the US and China. Nobody serious disputes any of that.
Here is the part worth sitting with. None of those three reasons required touching patent rights. NGT crops can still be patented. The traceability amendments failed. The patentability provisions did not. Funny, how that works out for the three companies large enough to file at scale, and considerably less funny for the seed cooperative that is not.
Two respected scientists disagree on whether "20 modifications" is even the right way to measure safety. Brussels picked a number, not a methodology. Sound familiar? It should. Every board approves a strategy this way. A pass mark that sounds rigorous enough that nobody asks who set it.

https://www.science-by-trianon.com/post/brussels-deregulated-gene-editing-to-save-the-planet-do-you-know-who-else-got-saved

Brussels deregulated gene-edited crops on 17 June 2026, citing climate adaptation, food security, and EU competitiveness. NGT-1 crops under 20 genetic modifications now skip risk assessment and traceability. But while labeling rules were dropped, patent rights for Bayer, Syngenta, and Corteva stayed...